Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephopathy (PROTECT): 2-year Results From a Randomised Active-Controlled Phase 3 Trial
The Lancet
2023
At Travere Therapeutics Global Medical Affairs,
we are dedicated to sharing scientific knowledge, collaborating with experts,
and innovation for improved rare disease outcomes.
The Lancet
2023
Find and connect your local Medical Science Liaison (MSL) for support related to Travere products.
Find your MSLHave questions?
Find scientific, evidence-based and balanced information about Travere products.